A 2026 Frontiers paper (European perspective) is highly relevant to pharma quality teams because it focuses on LLMs for process automation and compliance work (SOP automation, audit documentation, deviation management, compliance monitoring) and explicitly discusses the EU regulatory context (MDR/GDPR/EU AI Act). It also highlights the evaluation gap (lots of “accuracy-only” studies; little real-world deployment evidence) and argues for validation approaches that acknowledge non-determinism.